Can growth hormone secretagogues really make teens taller?

What did @fitfromelvin actually say?

The creator argued that growth hormone secretagogues, including hexarelin, ipamorelin, and MK-677, stimulate the pituitary to release more growth hormone, but that their effect during puberty is limited by two factors: the pituitary is already at peak GH output, and somatostatin acts as a feedback brake that counters any additional stimulus. They used this to explain why doctors treating short stature use injected GH rather than secretagogues, because injected GH "bypasses the pituitary and forces super physiological GH levels." The video stops short of recommending these compounds. It frames the whole thing as a reason secretagogues are "cope" for height gains, not a prescription.

Credit where it's due: this is a more nuanced take than most TikTok peptide content. The creator is not selling a stack or quoting bro-science forums. They are attempting to explain a real mechanism.

Does the science back this up?

Mostly, yes. The core mechanism is accurate, but the framing glosses over some important details that matter for a teenage audience. Puberty is indeed associated with amplified GH pulse amplitude, driven largely by rising sex steroids, particularly estradiol and testosterone, acting at the hypothalamic level. But "lifetime peak output" is an oversimplification that could mislead viewers into thinking more stimulation is simply impossible rather than potentially harmful.

The somatostatin feedback point is real. GH secretagogues work through the ghrelin receptor (GHSR-1a) or GHRH receptor, and endogenous negative feedback via somatostatin does blunt net GH output gains. A study by Popovic et al. (1995, Journal of Clinical Endocrinology and Metabolism) confirmed that GHRH-mediated GH release is subject to somatostatin counter-regulation, limiting the net effect. The claim that clinical trials in idiopathic short stature (ISS) use exogenous GH rather than secretagogues is also accurate. The 2003 FDA approval of recombinant GH for ISS was specifically based on supraphysiological delivery, not pituitary stimulation protocols.

What did they get wrong (or right)?

The biggest gap is what the creator left out entirely: safety. Saying secretagogues are limited in effect is not the same as saying they are safe for adolescents. MK-677, which the creator lists as an example, has been associated with increased fasting glucose, water retention, and elevated IGF-1 levels in clinical studies. Svensson et al. (1998, Journal of Clinical Endocrinology and Metabolism) found MK-677 raised IGF-1 by roughly 40 to 60 percent in young adults, which is not a trivial hormonal shift in a still-developing endocrine system.

The creator is also technically wrong to treat somatostatin as the sole limiter. Hepatic IGF-1 clearance, GH receptor sensitivity, and sleep architecture all influence net GH signaling. Framing it as a single brake hormone oversimplifies the system in a way that could leave viewers thinking "if I just override somatostatin, I win," which is not how this works and not what the creator intended to say.

The "your pituitary is already at peak output" line is close to accurate but imprecise. Peak GH secretion during puberty reflects pulse amplitude increases, not a hard ceiling on pituitary capacity. The distinction matters.

What should you actually know?

Adolescents watching this video should understand that "limited effect" and "safe to try" are not the same sentence. None of these compounds, including MK-677, ipamorelin, or hexarelin, are approved for use in minors outside of closely supervised clinical trials. The long-term effects of elevating IGF-1 and GH during a period when the endocrine system is already undergoing rapid change are not well characterized in healthy adolescents.

The clinical evidence for secretagogues improving height in normal-statured teenagers is essentially nonexistent. Studies on GH secretagogues in pediatric populations have focused on GH-deficient children, not healthy teens looking to add inches. If a teenager has genuine growth concerns, the appropriate path is an evaluation by a pediatric endocrinologist, not a TikTok-inspired peptide protocol.

• MK-677 is not a regulated pharmaceutical in most countries and is frequently sold as a research chemical with no quality controls.
• IGF-1 elevation during adolescence is not a neutral event. IGF-1 is a growth factor with roles in cell proliferation beyond muscle and bone.
• The video does not recommend these compounds, but its educational framing may normalize them for a young audience that will draw their own conclusions.